Stem cell therapy for advanced dry age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new stem-cell treatment for people with advanced dry age-related macular degeneration (AMD), a condition that causes blurring or loss of central vision. It aims to replace damaged cells in the back of the eye to potentially slow vision loss and improve day-to-day sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50 to 80 years old
- Have a specific type of advanced dry AMD (geographic atrophy) or a scar from previous wet AMD treatment that has stabilized
- Your vision in the study eye is poor but not completely blind (measured on a vision chart)
- If both eyes qualify, the worse-seeing eye will be studied
- No active eye infections, recent eye surgeries, or recent anti-VEGF injections (like Eylea or Lucentis) in the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The therapy is a painless light treatment that you might receive in multiple sessions, and the study aims to see if it can slow or improve vision decline.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This study tests a new treatment that uses your own stem cells to create retinal cells, which are then placed in your eye. The goal is to see if this can help improve vision for people with advanced age-related macular degeneration.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Hear when a new AMD - Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.